title: Clinical benefit as a primary efficacy endpoint.
authors.forename: E
authors.initials: E
authors.lastname: Ballatori
authors.forename: A
authors.initials: A
authors.lastname: Del Favero
authors.forename: F
authors.initials: F
authors.lastname: Roila
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine